Skip to content

AOCI at other companies

Eli Lilly logo
Eli LillyLLY
-$2.83B+24.9%
Amgen logo
AmgenAMGN
-$190M+17.7%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$856K-296%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$240K
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$8K
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$56K-75.2%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.3B+475%
Enterprise value$2.26B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s AOCI?
MBX Biosciences, Inc. (MBX) reported AOCI of -$606K in Q1 2026.
How has MBX Biosciences, Inc.'s AOCI changed year-over-year?
MBX Biosciences, Inc.'s AOCI decreased by 1243.4% year-over-year, from $53K to -$606K.
What is the long-term trend for MBX Biosciences, Inc.'s AOCI?
Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s AOCI has grown at a 118.3% compound annual growth rate (CAGR), from $60K to $286K.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.